# Surgical & Medical Robotics

## Sector Overview

Surgical robotics represents one of the highest-margin, most defensible segments within the broader robotics/automation investment universe. The global surgical robots market was valued at $13.69 billion in 2025 and is projected to reach $27.14 billion by 2030, growing at a 14.7% CAGR. More aggressive forecasts project $45.9 billion by 2035. Growth is driven by aging demographics, the global shift toward minimally invasive surgery (MIS), expanding procedure indications, and emerging market adoption. The sector benefits from razor-and-blade economics, deep regulatory moats, and high switching costs that create durable competitive advantages for established players.

Key tickers: **ISRG**, **SYK**, **MDT**, **JNJ**, **PRCT**, **GMED**

---

## Dominant Player: Intuitive Surgical (ISRG)

**Market Cap:** ~$176B (Feb 2026) | **2025 Revenue:** $8.35B (est.) | **Share of Soft-Tissue Surgical Robotics:** ~80%

### da Vinci Platform

Intuitive Surgical is the undisputed leader in surgical robotics, with an installed base of **11,106 da Vinci systems** as of December 31, 2025, up 12% from 9,902 at end of 2024. The company's competitive moat rests on three pillars: a massive installed base that creates switching costs, a razor-and-blade revenue model where instruments and accessories generate recurring revenue, and a training ecosystem that embeds da Vinci into surgical education globally.

**da Vinci 5 (Fifth Generation):** Launched in 2024, the da Vinci 5 is the company's most significant platform upgrade in over a decade, incorporating 150+ design innovations and 10,000x the computing power of the da Vinci Xi. Key differentiators include force feedback (surgeons deliver up to 43% less tissue force), AI-powered Case Insights for real-time performance analytics, in-console video replay, and integrated insufflation. In 2025, Intuitive placed **870 da Vinci 5 systems** (vs. 362 in 2024), with 303 placed in Q4 alone. Gross average selling price is approximately 30% higher than the Xi, though total acquisition cost is roughly 15% higher when accounting for previously separate accessories now integrated into da Vinci 5.

**Procedure Growth:** Da Vinci procedures grew approximately 18% for full year 2025, with Q4 growing 17%. The company guided 13-15% worldwide procedure growth for 2026, reflecting continued expansion into new specialties and geographies. The installed base growth of 12% combined with increasing utilization per system drives volume.

**Recurring Revenue Model:** Instruments and accessories represent over 60% of total revenue and grew 19% in 2025. Recurring revenue (instruments, accessories, and services) comprised approximately 85% of total revenue in Q3 2025. This annuity-like stream grows with each system placed and each procedure performed, as instruments have limited-use lifespans requiring regular replacement. Q4 2025 revenue was $2.87 billion, up 19% year-over-year.

**2026 Guidance:** Non-GAAP gross profit margin of 67-68%; procedure growth of 13-15%.

### Ion Bronchoscopy Platform

The Ion endoluminal system for robotic-assisted lung biopsy represents Intuitive's expansion beyond the operating room. As of mid-2025, over 900 Ion systems were installed across 10 countries, with more than 100 published abstracts and clinical studies involving 2,000+ subjects. In October 2025, the FDA cleared AI-enhanced software for Ion that addresses CT-to-body divergence using real-time computer vision combined with shape-sensing technology. A broader U.S. launch is planned for 2026. Ion directly competes with J&J's Monarch platform in the lung biopsy space.

### Investment Thesis

ISRG trades at a premium valuation (~55-60x forward earnings) justified by its dominant market position, high recurring revenue percentage, secular growth tailwinds, and expanding addressable market via new platforms (Ion) and geographies. The primary risk is da Vinci 5 cannibalization of Xi placements temporarily depressing system revenue, though this is a transition issue rather than structural. The 2026 procedure growth guidance deceleration from 18% to 13-15% reflects normalization, not deterioration.

---

## Orthopedic Robotics Leader: Stryker (SYK)

**Market Cap:** ~$141B (Jan 2026) | **2025 Revenue:** $25.1B | **2026 Revenue Guidance:** 8-9.5% organic growth

### Mako SmartRobotics

Stryker dominates orthopedic surgical robotics through its Mako platform, with an installed base exceeding **3,000 systems worldwide** and over 1.5 million cumulative Mako procedures. The company delivered record robot installations in Q4 2025, driven by the fourth-generation Mako 4 system.

**Product Expansion:** Mako has expanded beyond its original hip and knee applications into spine and shoulder:
- **Mako Spine:** First cases completed October 2024; limited market release through 2025 with full U.S. commercial launch expected H2 2025. Uses Q Guidance navigation modules for pedicle screw placement.
- **Mako Shoulder:** First cases completed late 2024, remaining in limited market release through 2025.
- **Mako 4:** A single robotics platform delivering all applications (Total Hip, Total Knee, Partial Knee, Spine), offering AI-driven planning, haptic feedback, and fourth-generation Q Guidance modules.

**Financial Performance:** The Orthopaedics segment climbed 9.7% to $2.36 billion in Q1 2025. Full year 2025 adjusted EPS rose 11.8% to $13.63, with 2026 guidance of $14.90-$15.10. Stryker achieved 100+ basis points of operating margin expansion for the second consecutive year. The MedSurg/Neurotechnology segments provide cross-selling synergies across the care pathway.

**Competitive Positioning vs. ISRG:** Stryker and Intuitive operate in largely complementary domains -- Stryker in orthopedics (hard tissue) and Intuitive in soft-tissue surgery. Overlap is minimal. Stryker's moat comes from bundling Mako with its dominant implant portfolio; hospitals that adopt Mako are locked into Stryker implants. The 10-15% market CAGR for joint replacement robotics through 2030 supports sustained growth.

### Handheld Robotics

In late 2025, Stryker began first cases with a handheld orthopedic robot designed for ambulatory surgical centers (ASCs), reflecting the industry trend toward lower-cost, compact robotic solutions for outpatient procedures.

---

## Emerging Challengers

### Johnson & Johnson (JNJ)

**Market Cap:** ~$500B (Dec 2025) | **2025 Revenue:** $94.2B | **MedTech Segment:** ~$33B

J&J is making the most ambitious push to challenge Intuitive Surgical's dominance in general surgery robotics, while simultaneously building a multi-platform robotic surgery portfolio.

**OTTAVA Robotic Surgical System:** J&J's flagship challenger to da Vinci, OTTAVA completed its first clinical cases in April 2025 (Roux-en-Y gastric bypass at Memorial Hermann-Texas Medical Center). In January 2026, J&J submitted OTTAVA to the FDA via the De Novo pathway for multiple upper-abdomen general surgery procedures (gastric bypass, gastric sleeve, small bowel resection, hiatal hernia repair). The company also received IDE approval for U.S. clinical trials in inguinal hernia. If cleared, OTTAVA would be the first credible competitor to da Vinci in high-volume general surgery. The timeline suggests potential FDA clearance in 2026-2027.

**MONARCH Platform:** Competes directly with Intuitive's Ion in robotic bronchoscopy. MONARCH QUEST received 510(k) clearance in March 2025 with AI-powered navigation algorithms. J&J is partnering with NVIDIA on AI for kidney stone procedures via the Monarch platform, with the urology version expected to be commercially available in the U.S. in 2026.

**VELYS Robotic-Assisted Solution:** Targets orthopedic surgery (knee replacement) and has expanded into spine. VELYS Spine received 510(k) clearance for spinal fusion procedure planning and instrumentation. First European cases for VELYS in UKA (unicompartmental knee arthroplasty) were completed in mid-2025. J&J is partnering with NVIDIA Isaac for Healthcare to advance AI across its robotic platforms.

**Strategic Outlook:** J&J is shifting its MedTech division from low-growth orthopedics toward high-growth cardiovascular and robotics. The company's ability to bundle OTTAVA with its massive surgical instrument and suture portfolio could create a compelling value proposition for hospitals. However, OTTAVA remains pre-revenue and years behind da Vinci's installed base advantage.

### Medtronic (MDT)

**Market Cap:** ~$127B (Jan 2026) | **TTM Revenue:** $34.75B | **Medical Surgical Segment:** ~$8.7B annually

**Hugo RAS System:** Medtronic's Hugo received FDA clearance for urologic procedures in December 2025, marking a major milestone after years of development. The clearance covers prostatectomy, nephrectomy, and cystectomy, supported by the Expand URO IDE study (137 patients across three urologic procedure types). Outside the U.S., Hugo has been used in tens of thousands of procedures across 30+ countries on five continents.

Medtronic plans a purposeful U.S. launch focusing on leading hospitals, with expected submissions for general surgery and gynecologic indications to follow. The Hugo platform differentiates through its modular design (individual arm carts vs. Intuitive's boom-mounted approach) and integration with Medtronic's LigaSure vessel-sealing technology (CE Mark received for Hugo). The Medical Surgical segment grew 2.1% in Q2 FY26, reflecting the early-stage commercial trajectory.

Hugo's competitive challenge is significant: entering the U.S. market years after da Vinci has become the standard of care, with a smaller clinical evidence base and no installed base advantage. However, Medtronic's global reach, existing hospital relationships, and ability to offer competitive pricing could enable penetration, particularly in emerging markets and cost-sensitive systems.

---

## Specialty Robotics Players

### Procept BioRobotics (PRCT)

**Market Cap:** ~$1.6B (Feb 2026) | **2025 Revenue:** ~$326M | **2026 Revenue Guidance:** $410-430M (26-32% growth)

Procept is a pure-play surgical robotics company focused exclusively on urology with its HYDROS Robotic System delivering Aquablation therapy for benign prostatic hyperplasia (BPH). Q3 2025 revenue was $83.3 million (up 43% YoY), with U.S. handpiece and consumable revenue growing 50%. The U.S. installed base reached 653 systems as of September 2025 (+58 in Q3). The BPH market represents 12+ million men in the U.S., with Aquablation positioned as a less invasive alternative to TURP. UBS initiated coverage in late 2025 with a profitability outlook targeting 2027. The razor-and-blade model (system placement drives recurring handpiece revenue) mirrors Intuitive's proven approach on a smaller scale.

### Globus Medical (GMED)

**Market Cap:** ~$11.9B (Feb 2026) | **2025 Revenue:** ~$2.94B | **2026 Revenue Guidance:** $3.18-3.22B

Globus Medical is the leading spine surgery robotics company, operating the ExcelsiusGPS platform -- the first robotic navigation system offering a comprehensive approach to spine and cranial procedures. Following the completed merger with NuVasive and acquisition of Nevro, Globus has become a diversified musculoskeletal powerhouse.

Q3 2025 sales hit $760 million (+22.9% YoY). Robot unit placements increased 59% YoY in Q2 2025, and robotic case volume grew 26% YoY. The ExcelsiusGPS system costs approximately $1.5 million per unit. The Enabling Technologies division delivered its best quarterly revenue performance in Q4 2025. The NuVasive integration is driving cross-selling, cost efficiencies, and realization of deferred tax assets. EPS guidance of $4.30-$4.40 for 2026 reflects continued margin expansion.

### Vicarious Surgical (RBOT)

**Market Cap:** ~$15.5M (Feb 2026) | **Stock Price:** ~$2.17 | **Pre-Revenue**

Vicarious Surgical represents a high-risk, speculative play on next-generation miniaturized surgical robotics. The company is developing a single-port robotic system featuring a VR headset for the surgeon, two disposable robotic arms, and a 3D camera -- all designed for a single 1.5cm incision. Originally valued at $1.1 billion through its 2021 SPAC with D8 Holdings, the stock has collapsed over 99%.

The company expects 2025 cash burn of $45 million (improved from $50M guidance) and 2026 cash burn of $35 million. Design freeze is expected toward end of 2026, with approximately $25 million in additional cash needs beyond existing resources. The company is outsourcing development components and has delayed its clinical timeline multiple times. The 52-week range of $1.81-$16.35 reflects extreme volatility. This is essentially a venture-stage bet at a micro-cap valuation.

---

## Other Notable Players

### CMR Surgical (Private, UK-based)

CMR Surgical has emerged as the most credible international challenger to Intuitive, with its Versius system becoming the second most utilized soft-tissue surgical robot globally. Over 40,000 procedures have been completed across 30+ countries and multiple specialties (colorectal, general, gynecology, thoracic, urology). The company raised $200M+ in April 2025 to accelerate commercialization and is reportedly exploring a potential sale at a ~$4 billion valuation (up from $3B in 2021).

Versius Plus, the next-generation system, received FDA 510(k) clearance for cholecystectomy in December 2025, with a U.S. launch planned for 2026. CMR also achieved CE Mark approval for pediatric surgery in January 2026, becoming only the third surgical robotics company (alongside Intuitive and China's SHUROI) to receive this designation in Europe. Versius differentiates through a modular, portable design with individual arm units versus da Vinci's integrated boom, appealing to smaller hospitals and ASCs.

### Asensus Surgical (Senhance) -- Acquired by Karl Storz

Karl Storz acquired Asensus Surgical for $0.35/share in August 2024. The Senhance system had accumulated 3,550+ procedures in 2023 (13% growth) across general surgery, gynecology, urology, colorectal, pediatric, and bariatric applications. The LUNA next-generation system submission was expected H2 2025 with clearance anticipated H1 2026. Under Karl Storz ownership, the platform gains access to a global distribution network and integration with visualization/endoscopy products.

### SS Innovations (India-based, Private)

SS Innovations performed the first robotic cardiac surgery in the Americas using its SSi Mantra 3 system in June 2025, with 80 systems installed across 75 hospitals primarily in India. The company is aiming for FDA clearance in 2026 and represents the emerging market cost disruption thesis.

---

## International Competition: China

### MicroPort MedBot (2252.HK)

MicroPort MedBot is the leading Chinese surgical robotics company, listed on the Hong Kong Stock Exchange. Its Toumai endoscopic surgical robot received NMPA market approval for clinical use across urology, general surgery, and gynecology. As of October 2025, cumulative global commercial orders reached 100+ units for Toumai, with nearly 80 installations completed.

In January 2025, MedBot's SkyWalker orthopedic robot performed its first total knee arthroplasty in South America (Brazil), demonstrating emerging market expansion. The China surgical robots market is expected to reach $3.8 billion by 2026 (11% global share, up from 5% in 2020), driven by government hospital modernization programs and domestic substitution policies favoring local manufacturers.

Chinese competitors are primarily a threat in the domestic and emerging market segments, where price sensitivity is highest. They are unlikely to challenge Intuitive or Stryker in the U.S./EU markets in the near term due to regulatory barriers and clinical evidence gaps.

---

## Rehabilitation Robotics

The rehabilitation robotics segment is smaller and earlier-stage than surgical robotics but growing rapidly, driven by aging populations, stroke rehabilitation demand, and improving reimbursement.

### Market Size

The medical exoskeleton market was valued at $1.41 billion in 2025, projected to reach $8.70 billion by 2035 (19.2% CAGR). Hospitals and rehabilitation centers held 47.4% market share in 2025, while the personal/home-care segment is growing fastest at 28.9% CAGR.

### Key Players

**Lifeward (LFWD, formerly ReWalk/Ekso Bionics):** The 2024 merger of Ekso Bionics and Lifeward (formerly ReWalk Robotics) created the largest publicly traded rehabilitation robotics company, combining industrial and rehab exoskeleton portfolios. Ekso Bionics holds approximately 17% global market share with FDA-cleared devices for mobility rehabilitation. In May 2025, Ekso joined NVIDIA's Connect program to develop a foundation model for human motion in rehabilitation using predictive movement analysis. Lifeward also partnered with AlterG to bundle anti-gravity treadmills with exoskeleton therapy.

**Bionik Labs (BNKL):** Develops the InMotion robotic therapy platform for stroke, MS, SCI, and Parkinson's rehabilitation. The number of U.S. hospitals using InMotion has increased threefold since 2019, with 250+ patients using the devices monthly through a Kindred hospitals partnership. The company remains small-cap and niche.

**Cyberdyne (Japan):** Develops the HAL (Hybrid Assistive Limb) exoskeleton for medical and industrial use. Maintains significant presence in Japan and Europe.

### Investment Considerations

Rehabilitation robotics companies are generally micro-cap with limited liquidity and long paths to profitability. The sector is better characterized as a thematic exposure rather than a core portfolio holding. The most investable exposure comes through diversified medtech players (Stryker, J&J) adding rehabilitation technologies to broader portfolios.

---

## AI-Assisted Diagnostics & Surgery

AI in medical imaging and diagnostics is rapidly converging with surgical robotics, creating a complementary investment theme.

### Market Size

The AI in medical imaging market was valued at approximately $1.36 billion in 2024, projected to reach $19.78 billion by 2033 (34.7% CAGR). By mid-2025, the FDA had cleared 873 total AI/ML medical device algorithms, with 115 added in the first half of 2025 alone. Radiology remains the largest single specialty for AI device clearances.

### Key Companies

**Viz.ai:** Deployed in 1,600+ hospitals, Viz.ai's AI platform identifies strokes on CT angiography and provides automated alerts, reducing time-to-treatment by approximately 66 minutes. The platform includes 13 cleared algorithms for stroke and neurocritical care. Viz.ai remains private.

**Aidoc:** Holds 20+ FDA clearances for AI-powered triage and prioritization across radiology workflows. The company raised over $200M and reports >90% sensitivity with low false-positive rates for its intracranial hemorrhage detection tool. Remains private.

**Paige AI (Acquired by Tempus, Aug 2025):** Paige developed a massive pathology foundation model trained on 1M+ slides in partnership with Microsoft. In April 2025, Paige received FDA Breakthrough Device designation for PanCancer Detect, the first AI tool designed to identify both common and rare cancer variants across multiple tissue types. Tempus launched Paige Predict in January 2026, a suite of digital pathology applications predicting clinically actionable biomarkers from H&E slides. The Tempus acquisition (TEM, public since June 2024) provides investable exposure to this space.

**GE Healthcare (GEHC):** Leads with 96 cleared AI radiology tools. **Siemens Healthineers (SHL.DE):** 80 cleared tools. **Philips (PHG):** 42 cleared tools.

### AI in Surgical Robotics

The convergence of AI with surgical robotics is accelerating: Intuitive's da Vinci 5 integrates Case Insights (AI-powered intraoperative analytics); J&J partnered with NVIDIA Isaac for Healthcare to develop AI for its robot platforms; Ion's latest software uses AI to correct CT-to-body divergence in real time. This convergence will increasingly differentiate next-generation platforms and deepen competitive moats.

---

## FDA Regulatory Pathways

Understanding FDA pathways is critical for assessing competitive dynamics and time-to-market:

### 510(k) Premarket Notification
The most common pathway for iterative improvements to existing surgical robots. Requires demonstration of "substantial equivalence" to a predicate device. Faster review (typically 3-6 months) and lower cost. Used for: Stryker Mako expansions, CMR Versius Plus, MONARCH QUEST, VELYS Spine.

### De Novo Classification
For novel, low-to-moderate risk devices without a predicate. Creates a new product classification that future 510(k) submissions can reference. Since 2021, FDA allows "direct to De Novo" submissions. Used for: CMR Versius (original, Oct 2024), J&J OTTAVA (submitted Jan 2026). The De Novo pathway creates a lasting regulatory moat: the first company through establishes the predicate for all followers.

### Premarket Approval (PMA)
Most stringent pathway for Class III (high-risk) devices. Requires clinical trial data demonstrating safety and efficacy. Longest review times and highest costs. There is growing speculation that future highly autonomous (Level 4-5) surgical robots may require PMA, raising the regulatory bar significantly. This would further entrench established players.

### Regulatory Moat Dynamics
The FDA's eSTAR electronic format requirement (mandatory for all 510(k) and De Novo submissions from Oct 2025) standardizes submissions but doesn't reduce the clinical evidence burden. "Predicate creep" -- where iterative 510(k) clearances gradually advance technology well beyond the original predicate -- is a recognized concern in surgical robotics that may lead to tighter regulatory scrutiny. Companies with deep regulatory affairs expertise and large clinical evidence databases (Intuitive, Stryker, Medtronic) hold structural advantages.

---

## Competitive Dynamics & Market Structure

### Switching Costs
Surgical robots exhibit extraordinarily high switching costs:
- **Capital investment:** $1.5-2.5M per system
- **Surgeon training:** 100+ hours of specialized training per surgeon, typically certified on one platform
- **Workflow integration:** OR scheduling, staff training, instrument inventory all optimized around installed system
- **Clinical data:** Surgeons build case libraries and outcome data on their platform
- **Regulatory/credentialing:** Hospital credentialing committees certify surgeons on specific platforms

These switching costs create customer lifetime values measured in decades, not years.

### Razor-and-Blade Economics
The surgical robotics business model is inherently recurring:
- System placement (capital sale or operating lease)
- Per-procedure instrument/accessory revenue (limited-use instruments must be replaced)
- Service contracts (annual maintenance)
- Software/data subscriptions (emerging revenue stream)

Intuitive's 85% recurring revenue percentage demonstrates the model at maturity.

### ASC Expansion
Ambulatory surgical centers represent a 15% CAGR growth vector through 2030 as payors shift lower-acuity procedures to outpatient settings. This favors compact, cost-efficient robotic systems and opens market segments where smaller competitors (CMR Surgical, Stryker's handheld robot) can compete without challenging Intuitive's hospital stronghold.

---

## Risk Factors

1. **Valuation risk (ISRG):** At 55-60x forward earnings, any deceleration in procedure growth or margin compression could trigger significant multiple contraction. The stock declined 11.6% in market cap over a single 30-day period in early 2026.

2. **Competitive disruption:** J&J's OTTAVA, Medtronic's Hugo, and CMR's Versius all represent credible long-term threats to Intuitive's dominance. While switching costs protect the installed base, new hospital systems and emerging markets are contestable.

3. **Reimbursement pressure:** Healthcare payors increasingly scrutinize the cost-effectiveness of robotic surgery vs. laparoscopic or open alternatives. If differential reimbursement narrows, the value proposition weakens.

4. **Regulatory tightening:** FDA concerns about predicate creep and autonomous AI integration could slow product iterations and raise compliance costs, particularly for next-generation platforms.

5. **Tariffs and trade policy:** Surgical robots have global supply chains; tariff escalation could impact margins and pricing, particularly for companies manufacturing in or sourcing from China.

6. **China competitive risk:** Government-backed domestic substitution policies in China's $3.8B surgical robot market could limit Western companies' addressable market in the world's second-largest healthcare system.

7. **Technology risk for early-stage players:** Companies like Vicarious Surgical (RBOT) face existential risk from cash burn, clinical timeline delays, and the possibility that their technology never achieves commercial viability.

8. **Concentration risk:** Intuitive derives the vast majority of its revenue from a single platform (da Vinci). Any safety event, recall, or competitor breakthrough targeting da Vinci's core indications would be highly impactful.

---

## Investment Summary

| Company | Ticker | Market Cap | 2025 Rev | Growth | Thesis |
|---------|--------|-----------|----------|--------|--------|
| Intuitive Surgical | ISRG | $176B | $8.35B (est.) | 18% proc. growth | Dominant leader, 85% recurring, da Vinci 5 cycle |
| Stryker | SYK | $141B | $25.1B | 10.3% organic | Ortho robotics leader, Mako expansion into spine/shoulder |
| J&J | JNJ | $500B | $94.2B | 6% total | OTTAVA launch 2026-27, Monarch/Velys portfolio |
| Medtronic | MDT | $127B | $34.75B TTM | 5.5% organic | Hugo FDA cleared Dec 2025, global rollout underway |
| Procept BioRobotics | PRCT | $1.6B | $326M | 43% Q3 YoY | Pure-play urology, path to profitability 2027 |
| Globus Medical | GMED | $11.9B | $2.94B | 22.9% Q3 YoY | Spine robotics leader, NuVasive synergies |
| Vicarious Surgical | RBOT | $15.5M | Pre-rev | N/A | Speculative, micro-cap, design freeze 2026 |

**Top Picks for Portfolio Construction:**

- **Core holding:** ISRG -- Despite premium valuation, the combination of market dominance, recurring revenue, da Vinci 5 upgrade cycle, and Ion platform expansion makes this the highest-conviction name in surgical robotics. Position sizing should reflect the valuation premium.

- **Diversified medtech:** SYK -- Mako's expansion into spine and shoulder, combined with Stryker's broader MedSurg portfolio, provides robotics exposure with lower single-product concentration risk. Attractive for investors seeking robotics growth within a diversified healthcare framework.

- **Growth compounder:** GMED -- Post-NuVasive merger integration is driving revenue acceleration and margin expansion. The ExcelsiusGPS platform's 59% robot unit placement growth demonstrates strong adoption. Reasonable valuation relative to growth rate.

- **Pure-play growth:** PRCT -- Highest revenue growth rate in the group with a large untapped BPH market. Pre-profitability with 2027 breakeven target. Higher risk but significant upside if Aquablation adoption continues its trajectory.

- **Avoid:** RBOT -- Pre-revenue, repeated clinical timeline delays, micro-cap with potential dilution risk. The technology is interesting but the company may not survive to commercialize it.

---

## Sources

- [Intuitive Surgical Q4 2025 Earnings](https://www.globenewswire.com/news-release/2026/01/22/3224266/7637/en/Intuitive-Announces-Fourth-Quarter-Earnings.html)
- [Intuitive Surgical Preliminary Q4/FY2025 Results](https://isrg.intuitive.com/news-releases/news-release-details/intuitive-announces-preliminary-fourth-quarter-and-full-year-5)
- [Intuitive Surgical Q3 2025 Earnings](https://isrg.intuitive.com/news-releases/news-release-details/intuitive-announces-third-quarter-earnings-5)
- [ISRG Market Cap - Meyka](https://meyka.com/blog/isrg-intuitive-surgical-nasdaq-248-48815-06-feb-2026-ai-stocks-view-0702/)
- [Intuitive Surgical da Vinci 5 Features](https://www.intuitive.com/en-us/products-and-services/da-vinci/5)
- [da Vinci 5 SAGES Technology Assessment](https://www.sages.org/publications/tavac/da-vinci-5/)
- [Intuitive Surgical Ion AI Enhancements](https://investor.intuitivesurgical.com/news-releases/news-release-details/intuitive-expands-ai-and-advanced-imaging-integration-ion)
- [Stryker FY25 Results and 2026 Outlook](https://finance.yahoo.com/news/stryker-enters-2026-strong-momentum-125630968.html)
- [Stryker Q4 2025 Results](https://www.stocktitan.net/news/SYK/stryker-reports-2025-operating-results-and-2026-dgwz6rabuqz7.html)
- [Stryker Mako Next Generation at AAOS 2025](https://www.prnewswire.com/news-releases/stryker-showcases-next-generation-of-mako-smartrobotics-at-aaos-2025-annual-meeting-302397425.html)
- [Stryker Mako Installed Base and Market Position](https://www.therobotreport.com/stryker-leads-orthopedic-surgery-robots/)
- [Stryker Handheld Ortho Robot](https://www.medtechdive.com/news/stryker-starts-first-cases-with-handheld-ortho-robot/810982/)
- [J&J OTTAVA First Cases](https://www.jnj.com/media-center/press-releases/johnson-johnson-medtech-announces-completion-of-first-cases-with-ottava-robotic-surgical-system)
- [J&J OTTAVA FDA Submission](https://www.jnj.com/media-center/press-releases/johnson-johnson-submits-ottava-robotic-surgical-system-to-the-u-s-food-and-drug-administration)
- [J&J MONARCH QUEST Clearance](https://www.jnj.com/media-center/press-releases/johnson-johnson-medtech-announces-clearance-of-monarchtm-quest-for-enhanced-robotic-assisted-bronchoscopy)
- [J&J VELYS Spine Launch](https://www.medtechdive.com/news/jnj-launches-velys-spine-surgical-robot/723253/)
- [J&J NVIDIA Robotics Partnership](https://www.jnj.com/media-center/press-releases/johnson-johnson-to-advance-robotics-development-with-nvidia-isaac-for-healthcare)
- [J&J MedTech Growth Strategy](https://www.massdevice.com/johnson-johnson-medtech-chair-schmid-robotics-portfolio-realignment-will-define-next-growth-phase/)
- [Medtronic Hugo FDA Clearance](https://news.medtronic.com/2025-12-03-Medtronic-announces-FDA-clearance-of-Hugo-TM-robotic-assisted-surgery-system-for-urologic-surgical-procedures)
- [Medtronic Q2 FY26 Results](https://news.medtronic.com/2025-11-18-Medtronic-reports-strong-second-quarter-fiscal-2026-financial-results,-enterprise-growth-drivers-accelerate-momentum)
- [PROCEPT BioRobotics Q3 2025 Results](https://www.globenewswire.com/news-release/2025/11/04/3180832/0/en/PROCEPT-BioRobotics-Reports-Third-Quarter-2025-Financial-Results-and-Issues-2026-Revenue-Guidance.html)
- [PROCEPT BioRobotics 2026 Revenue Guidance](https://seekingalpha.com/news/4515322-procept-biorobotics-outlines-410m-430m-2026-revenue-target-while-accelerating-utilization)
- [Globus Medical Q4 2025 Results](https://finance.yahoo.com/news/globus-medical-gmed-valuation-check-220833454.html)
- [Globus Medical 2026 Revenue Guidance](https://www.sahmcapital.com/news/content/why-globus-medical-gmed-is-up-82-after-raising-2026-revenue-guidance-and-integration-outlook-2026-01-11)
- [Globus Medical ExcelsiusGPS](https://www.globusmedical.com/musculoskeletal-solutions/excelsiustechnology/excelsiusgps/)
- [Vicarious Surgical 2026 Cash Burn Guidance](https://www.businesswire.com/news/home/20251215000624/en/Vicarious-Surgical-Announces-Full-Year-2026-Cash-Burn-Guidance)
- [Vicarious Surgical Timeline Delays](https://www.massdevice.com/vicarious-surgical-robot-timeline-delay-q3-2025/)
- [CMR Surgical $200M Fundraise](https://us.cmrsurgical.com/news/cmr-surgical-secures-200m-usd-in-funding)
- [CMR Surgical Versius Plus FDA Clearance](https://www.medtechdive.com/news/CMR-Surgical-FDA-clearance-Versius-Plus-robot/808140/)
- [CMR Surgical Potential $4B Sale](https://thespinemarketgroup.com/cmr-surgical-considers-potential-4-billion-sale-amid-global-expansion-of-versius-robot/)
- [Karl Storz Acquires Asensus Surgical](https://pitchbook.com/profiles/company/53502-13)
- [MicroPort MedBot Toumai Orders](https://microport.com/news/microport-medbot-surpasses-130-global-orders-and-achieves-milestone-in-telesurgery)
- [MicroPort MedBot NMPA Approval](https://microport.com/news/microport-medbot-s-toumai-sp-laparoscopic-surgical-robot-receives-nmpa-market-approval-in-china)
- [Surgical Robots Market Forecast - MarketsandMarkets](https://www.marketsandmarkets.com/Market-Reports/surgical-robots-market-256618532.html)
- [Surgical Robotics Market - Precedence Research](https://www.precedenceresearch.com/surgical-robotics-market)
- [Medical Exoskeleton Market - Fortune Business Insights](https://www.fortunebusinessinsights.com/medical-exoskeleton-market-115112)
- [Rehabilitation Robots Market - Mordor Intelligence](https://www.mordorintelligence.com/industry-reports/rehabilitation-robots-market)
- [AI in Medical Imaging Market - Grand View Research](https://www.grandviewresearch.com/industry-analysis/artificial-intelligence-medical-imaging-market)
- [AI Radiology Trends 2025 - IntuitionLabs](https://intuitionlabs.ai/articles/ai-radiology-trends-2025)
- [Tempus/Paige Predict Launch](https://tissuepathology.com/2026/01/21/tempus-announces-the-launch-of-paige-predict/)
- [FDA Regulatory Pathways - Educo](https://educolifesciences.com/choosing-the-right-fda-submission-pathway-for-your-medical-device/)
- [FDA De Novo Pathway Guide](https://www.complizen.ai/post/de-novo-fda-pathway-complete-guide)
- [Surgical Robotics Competitive Landscape - Life Science Intelligence](https://www.lifesciencemarketresearch.com/insights/2025-surgical-robotics-market-trends-and-key-innovators)
- [Robotic Surgery Market Growth - Towards Healthcare](https://www.towardshealthcare.com/insights/robotic-surgery-market-sizing)
